B

한국유니온제약

080720KOSDAQ

62.8 / 100

Reference Date: 2026-09-08

Financial Score26.5 / 40
News Sentiment21.3 / 25
Momentum5.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but Revenue is on a declining trend. Declined 11.6% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Korea Union Pharmaceutical focuses on manufacturing and selling specialty pharmaceuticals, exporting finished drugs, and providing CMO (contract manufacturing) services. The company specializes in antibiotics, cardiovascular, and musculoskeletal products, leveraging its GMP facilities and R&D efforts to enhance profitability. It has expanded exports to regions such as the Middle East, Southeast Asia, and South America, and is further expanding its CMO business and product portfolio through a newly completed factory.

Number of Employees

123people

Average Salary

39.2M KRW

Score Calculation Basis

Detailed Financial Score

PER
Industry Average 15.004.0Point
PBR
Industry Average 1.203.5Point
ROE
419.43Industry Average 8.007.0Point

52.4x industry avg (excellent)

Debt Ratio
-21.02Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20254.0 / 10 points
Revenue Growth Rate
0.0 / 3

Avg ▼23.9% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼92.6% (2-year basis)

ROE Trend
4.0 / 4

Avg ROE 88.4% (improving, 3yr)

Detailed News Sentiment

1 totalPositive 1Neutral 0Negative 0Average Sentiment Score 85

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 2,410Won52-week high 2,72552-week low 2,410
1-month return1.0Point

1m -11.56% (falling)

Volume trend3.0Point

Volume flat

Detailed Disclosure

13 totalPositive 3Neutral 8Negative 2
  • Neutral주주명부폐쇄기간또는기준일설정2026-09-01
  • Neutral주주총회소집결의 (임시주주총회)2026-09-01
  • Neutral기타시장안내 (관리종목 지정 사유 일부 해제 관련 시장조치 미진행)2026-08-31
  • Negative회생절차종결결정2026-08-31
  • Neutral주권매매거래정지기간변경 (투자자 보호)2026-08-27